EA200970403A1 - Бициклические триазолы в качестве модуляторов протеинкиназы - Google Patents

Бициклические триазолы в качестве модуляторов протеинкиназы

Info

Publication number
EA200970403A1
EA200970403A1 EA200970403A EA200970403A EA200970403A1 EA 200970403 A1 EA200970403 A1 EA 200970403A1 EA 200970403 A EA200970403 A EA 200970403A EA 200970403 A EA200970403 A EA 200970403A EA 200970403 A1 EA200970403 A1 EA 200970403A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulators
proteinkinase
bicyclic triazoles
triazoles
bicyclic
Prior art date
Application number
EA200970403A
Other languages
English (en)
Russian (ru)
Inventor
Пьер-ив Буно
Кристофер Рональд Смит
Элизабет Энн Джефферсон
Original Assignee
ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. filed Critical ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК.
Publication of EA200970403A1 publication Critical patent/EA200970403A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA200970403A 2006-10-23 2007-10-18 Бициклические триазолы в качестве модуляторов протеинкиназы EA200970403A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87030906P 2006-12-15 2006-12-15
US91376607P 2007-04-24 2007-04-24
US95284007P 2007-07-30 2007-07-30
PCT/US2007/081841 WO2008051808A2 (en) 2006-10-23 2007-10-18 Bicyclic triazoles as protein kinase modulators

Publications (1)

Publication Number Publication Date
EA200970403A1 true EA200970403A1 (ru) 2009-10-30

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970403A EA200970403A1 (ru) 2006-10-23 2007-10-18 Бициклические триазолы в качестве модуляторов протеинкиназы

Country Status (25)

Country Link
US (1) US8507489B2 (enExample)
EP (1) EP2084162B1 (enExample)
JP (1) JP5378222B2 (enExample)
KR (1) KR20090071612A (enExample)
AR (1) AR063520A1 (enExample)
AU (1) AU2007309149C1 (enExample)
BR (1) BRPI0717320A2 (enExample)
CA (1) CA2667428A1 (enExample)
CO (1) CO6190620A2 (enExample)
CR (1) CR10803A (enExample)
DK (1) DK2084162T3 (enExample)
EA (1) EA200970403A1 (enExample)
ES (1) ES2393130T3 (enExample)
IL (1) IL197958A0 (enExample)
MA (1) MA30871B1 (enExample)
MX (1) MX2009004059A (enExample)
NO (1) NO20091618L (enExample)
NZ (1) NZ575336A (enExample)
PE (1) PE20080893A1 (enExample)
PL (1) PL2084162T3 (enExample)
PT (1) PT2084162E (enExample)
SV (1) SV2009003235A (enExample)
TN (1) TN2009000142A1 (enExample)
TW (1) TW200835492A (enExample)
WO (1) WO2008051808A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649976C2 (ru) * 2013-03-13 2018-04-06 Ф. Хоффманн-Ля Рош Аг Способ получения бензоксазепиновых соединений

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
PL2719699T3 (pl) 2009-12-31 2016-01-29 Hutchison Medipharma Ltd Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
US20130324526A1 (en) * 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
MX339302B (es) * 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
MX2014011987A (es) 2012-04-03 2014-11-10 Novartis Ag Combinaciones de inhibidores de cinasa de tirosina y su uso.
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (en) * 2012-12-10 2014-06-19 Abbvie Inc. Triazinone compounds
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
US20150152122A1 (en) * 2013-03-13 2015-06-04 Avon Products, Inc. Tyrosinase inhibitors
WO2014164195A1 (en) 2013-03-13 2014-10-09 Avon Products, Inc Tyrosinase inhibitors
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
WO2014180182A1 (zh) * 2013-05-10 2014-11-13 江苏豪森药业股份有限公司 [1,2,4]三唑并[4,3-a]吡啶类衍生物，其制备方法或其在医药上的应用
WO2017049711A1 (zh) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
EP0228061A3 (en) * 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Cephem compounds
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002083675A2 (en) * 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
WO2004058769A2 (en) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
EP2239262A3 (en) * 2004-07-27 2011-10-19 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
ES2355923T3 (es) 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
WO2006071548A2 (en) 2004-12-27 2006-07-06 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649976C2 (ru) * 2013-03-13 2018-04-06 Ф. Хоффманн-Ля Рош Аг Способ получения бензоксазепиновых соединений

Also Published As

Publication number Publication date
AU2007309149C1 (en) 2013-04-04
PL2084162T3 (pl) 2013-01-31
EP2084162B1 (en) 2012-09-12
AR063520A1 (es) 2009-01-28
MX2009004059A (es) 2009-04-27
DK2084162T3 (da) 2012-10-01
US8507489B2 (en) 2013-08-13
CR10803A (es) 2009-06-16
US20090258855A1 (en) 2009-10-15
EP2084162A2 (en) 2009-08-05
WO2008051808A3 (en) 2008-07-24
AU2007309149A1 (en) 2008-05-02
CA2667428A1 (en) 2008-05-02
PE20080893A1 (es) 2008-08-26
PT2084162E (pt) 2012-10-09
WO2008051808A2 (en) 2008-05-02
TN2009000142A1 (en) 2010-10-18
CO6190620A2 (es) 2010-08-19
NZ575336A (en) 2012-04-27
KR20090071612A (ko) 2009-07-01
IL197958A0 (en) 2009-12-24
JP2010507578A (ja) 2010-03-11
AU2007309149B2 (en) 2012-09-06
TW200835492A (en) 2008-09-01
MA30871B1 (fr) 2009-11-02
ES2393130T3 (es) 2012-12-18
BRPI0717320A2 (pt) 2013-10-22
JP5378222B2 (ja) 2013-12-25
NO20091618L (no) 2009-05-22
SV2009003235A (es) 2009-10-15

Similar Documents

Publication Publication Date Title
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
EA200970738A1 (ru) Ингибиторы активности akt
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200900959A1 (ru) Ингибиторы мек
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
TW200745109A (en) Pyrrolo-pyridine kinase modulators
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
TW200801008A (en) Protein kinase inhibitors
EA201070247A1 (ru) Ингибиторы протеасом
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201170344A1 (ru) Азаиндольные ингибиторы iap
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen